CONSUN PHARMA (01681) has announced its decision to implement a share repurchase plan. The plan will be executed under the general mandate granted to the board by the company's shareholders at the annual general meeting held on May 26, 2026, authorizing the repurchase of company shares. The repurchases will be conducted on the open market.

The total amount of funds available for the proposed share repurchases is up to HKD 200 million. In accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the repurchase price per share shall not exceed 5% of the average closing price of the shares for the five trading days immediately preceding each repurchase.

The board expressed strong confidence in the company's business development and future prospects. It believes that the current share price does not fully reflect the company's intrinsic value or the value recognized by investors. Depending on prevailing market conditions and funding arrangements, the board considers the share buyback plan to be in alignment with the company's long-term strategic development.

The implementation of this share repurchase plan is expected to optimize the management of the company's capital structure and serve the overall interests of the company and its shareholders.